Company Overview and News
Philip Morris has increased its dividend for 10 of the last ten years in a row and presently has a yield of 5.6%, which is well above average.
HD PM GE GEC ADP ADPVV JNJ IR KHC GNE OHI BA MO
The Fed Chair is very sanguine on the outlook for the U.S. economy going forward, supporting his intent to proffer two more raises this year.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
Anyone paying even the least amount of attention to the tobacco industry is cognizant of the fact that Philip Morris (PM) is putting a full-court press on getting its IQOS smokeless product to surpass, supplant and replace tobacco products like cigarettes.
SOJA PM GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR NDAQ ROKU CLDT VZ WPC OHI
When sanity and reality returns, investors will flock back into the likes of Boeing, Raytheon and Lockheed Martin for safety, capital appreciation and income.
SOJA LMT GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
Last month I wrote about my DGI portfolio that I keep in an IRA account. Below is a chart from that article showing the dividends collected since 2015 by month. I have a goal of increasing dividends each year by 12% from the prior year's dividends, and since 2015 this DGI portfolio has met or exceeded that goal. While I was on track to meet my goal for 2018, my one concern was that the dividends collected in March of 2018 didn't exceed those collected in March of 2017.
SOJA SO STAG.PRB EPR.PRG STAG.PRC LTC STOR NEE.PRI NEE.PRJ LADR NEE.PRC AAPL NEE.PRQ NEE.PRR OHI STAG MCD NEE STAG.PRA
This article is Update 29 (and the last) to my original article entitled "If I Had to Build An Income Portfolio Today".
GEO UNIT STAG.PRB STAG.PRC EPD TD SBRA STWD.WI VZA CALM WELL STAG TD HASI STAG.PRA SBRAP VTR DOC PEGI RY TNTTF VDE IRM RY ORI CLDT WES PEG VZ STWD OHI
Realized total return on portfolio investment for May from dividends and swing trades was +1.57% (a monthly record) and totals +6.80% for 7 months.
CLNS GEC GE CLNS.PRJ CLNS.PRI CLNS.PRH CLNS.PRG CLNS.PRE CLNS.PRD GDOT CLNS.PRB MIC GNE OHI
Which dividend stocks are currently on my watch-list and what looks attractive for a new position.
ETP.PRC PG TWX SKT EPD ENB STWD.WI KO AGNC NRZ NLY NLY.PRA NLY.PRECL TWC NLY.PRD NLY.PRE NLY.PRC ENB NLY.PRF ETP BP NLY.PRG T STWD OHI
Turn anxiety and uncertainty into higher income with this REIT, rebounding with directional change in interest rates.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA BAC SUI MSCA HMNY ED MO GOV SO BAC ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to OHI / Omega HealthCare Investors, Inc. on message board site Silicon Investor.
as of ET